Laurent Fischer, Adverum CEO
Adverum lays off 38% of staff as it enters new trial for ocular gene therapy after last year's safety woes
Adverum is moving forward with its eye disease gene therapy that caused headaches in April 2021, but is doing so with fewer staff on board …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
